Therapeutic area

Myasthenia gravis

Developing digital tools to study fluctuating muscle weakness and its effects on movement, speech, eye function, and daily life in myasthenia gravis.

Myasthenia gravis (MG) is a chronic autoimmune disease that causes muscle weakness, typically worsening with activity and improving with rest. Symptoms can include drooping eyelids (ptosis), double vision (diplopia), slurred speech (dysarthria), and difficulty chewing, swallowing, or breathing.

Talk to our team Explore our research

MG research supported by $2.5 million in NIH funding

With support from the NIH, we are combining wearable sensors, speech and video assessments, and patient-reported outcomes to study MG symptoms and their impact on daily life.

Explore our clinical studies

Our research in MG

Our research focuses on three complementary areas: developing digital measures of MG-related function, studying changes during treatment in daily life, and building longitudinal datasets to complement clinical trial data.

Digital measures for studying MG symptoms

We are developing digital assessments with MG experts and input from people living with MG. Our approach combines wearable measurements of activity and movement with speech, video, and breathing assessments. Patient-reported outcomes provide context on symptoms, fatigue, and daily function.

  • PAMSys

    Wearable sensors that measure physical activity, posture, and walking patterns to study their relationships with MG symptoms and reported fatigue.

  • PAMSys ULM

    Wrist-worn sensors that track upper limb movement during everyday activities, supporting research on arm use and function.

  • BioDigit Watch

    A smartwatch-based wearable for tracking physical activity and movement patterns over time in daily life.

  • BioDigit Speech

    Standardized speech recordings and automated analysis to study speech characteristics and changes associated with dysarthria.

  • Ocular assessments

    Guided video recordings with BioDigit Video to assess eyelid drooping (ptosis) and visible eye movements.

  • Respiratory assessment

    At-home lung function measurements using an integrated spirometer as part of the study assessment protocol.

Evidence for digital monitoring in MG

A published pilot study evaluated the feasibility and acceptability of collecting speech, video, wearable, and patient-reported data in MG. Conference presentations also report exploratory relationships between wearable activity measures and clinical assessments, providing a foundation for further validation.

  • Multimodal monitoring

    Feasibility of multimodal remote monitoring

    A 2025 Digital Biomarkers study involving 20 people with MG reported successful data collection and transfer during the pilot. Interviews with participants and five clinicians supported its usability and acceptability, informing larger validation studies.

  • Wearable monitoring

    Wearable measures and clinical assessments

    A 2025 AAN conference abstract reported associations between seven days of wearable activity data and MG clinical scores and patient-reported outcomes in 20 people with MG. These exploratory findings support further evaluation.

Generating real-world evidence with digital measures in MG

Our BioDigit MG3 observational study (NCT07226830) is designed to follow people with generalized MG for 16 weeks across two treatment cycles of an approved therapy. It aims to examine changes in digital measures and patient-reported outcomes and to explore whether early digital changes are associated with later clinical outcomes.

View the study on ClinicalTrials.gov (opens in a new tab)

Our clinical studies in MG

Our MG studies combine wearable data and digital assessments to explore symptoms and function, with assessment periods from seven days to 12 months. Enrollment figures below are planned totals. Statuses reflect registry updates from March 2024 (MG) and November 2025 (MG2/MG3), checked in September 2026. Follow the study links for recruitment details.

Our research partners

Our MG research brings together expertise from academic medicine, patient advocacy, and industry.

  • Massachusetts General Hospital
  • Muscular Dystrophy Association
  • Myasthenia Gravis Foundation of America
  • UCB

Selected publications and presentations

Advance MG research with digital measures

Plan digital assessments for your MG study. Discuss research collaborations, study protocols, and data access with our team.

Talk to our team